Framework · Service Journalism

How to evaluate a compounding pharmacy

Ten public-record criteria we use to assess any 503A or 503B compounder. Every data source is free and available online. The purpose is literacy — we do not rate specific pharmacies on this page.

Not medical advice. This framework helps you evaluate a pharmacy’s regulatory profile. It does not evaluate whether any compounded preparation is safe or appropriate for you, and it is not an endorsement of any pharmacy. See our Medical Disclaimer.

What this framework is, and isn’t

✓Applies to licensed US 503A and 503B compounding pharmacies.
✓Uses only public-record data — licenses, 483s, warning letters, disciplinary orders, recalls, CoAs.
✓Designed to be replicable — anyone following these steps should reach similar conclusions from the same sources.
✗Not for research-chemical vendors, grey-market peptide resellers, or any entity that is not a licensed compounding pharmacy. Those sit outside the US regulatory framework and require a different evaluation approach.
✗Not a buy-it-or-avoid-it recommendation. This is literacy, not advice.

The 10 criteria

State board of pharmacy license

What it measures: Current, active pharmacy license in the state the pharmacy operates from, and separate non-resident licenses in every state they ship to.

Where to look: Look up the pharmacy by name on the state board of pharmacy website for the state their street address sits in. Every state has an online license lookup. Then repeat for your own state if it is different.

Red flags: License lapsed, suspended, disciplinary order on file, or no license listed in the state you live in.

PCAB accreditation

What it measures: Pharmacy Compounding Accreditation Board accreditation is voluntary, but it indicates the pharmacy has been independently audited against USP chapter standards.

Where to look: Search the ACHC PCAB directory (achc.org) by pharmacy name. Verify the accreditation is current, not lapsed.

Red flags: Pharmacy claims PCAB accreditation but is not listed in the directory. Expired accreditation described as current.

FDA 483 observation history

What it measures: Form 483 observations are what FDA inspectors write down when they find problems during an inspection. The number, severity, and recurrence of observations is a strong quality signal.

Where to look: Search the pharmacy name on FDA’s public 483 database and the FDA Inspection Dashboard. Read every observation, not just the headline count.

Red flags: Repeat observations on sterility, environmental monitoring, or personnel practices. Any Official Action Indicated (OAI) disposition.

FDA warning letter history

What it measures: Warning letters escalate above 483s and are public. They describe violations FDA considers significant enough to warrant formal correspondence.

Where to look: Search the FDA Warning Letters database for the pharmacy and any parent company.

Red flags: Any warning letter in the last five years. Unresolved warning letters. Warning letters on peptide-specific preparations.

USP 795 / 797 / 800 compliance

What it measures: USP chapters set standards for non-sterile (795), sterile (797), and hazardous (800) compounding. Peptide preparations are typically sterile 797 work.

Where to look: Ask the pharmacy directly for their current USP 797 compliance documentation. A compliant pharmacy will share summary documentation without hesitation.

Red flags: Vague or deflecting answers. No documented environmental monitoring program. No documented competency testing.

State disciplinary action history

What it measures: State boards of pharmacy publish disciplinary orders, including license probation, suspension, and surrender actions.

Where to look: State board of pharmacy disciplinary action database for every state the pharmacy holds a license in.

Red flags: Orders related to sterility, mislabeling, unapproved substance compounding, or fraudulent billing.

Recall and adverse event history

What it measures: Compounded preparations can be voluntarily recalled by the pharmacy or under FDA pressure. MedWatch captures associated adverse events.

Where to look: FDA Enforcement Report database (recalls), FDA MedWatch, and the pharmacy’s own published recall notices.

Red flags: Recent recalls, especially sterility-related. Pattern of recalls. Unpublished recalls mentioned in MedWatch.

Third-party potency and sterility testing

What it measures: Reputable compounders send finished preparations to an independent lab for potency assay, sterility testing, and endotoxin testing. Frequency and test results should be shareable on request.

Where to look: Ask the pharmacy to see a recent Certificate of Analysis (CoA) for a preparation you are actually getting. Verify the testing lab is an accredited independent facility, not the compounder itself.

Red flags: No CoA available. CoA is from the compounder’s own in-house lab. Test methods do not match USP chapters.

Operational transparency

What it measures: A legitimate pharmacy publishes its license numbers, physical address, named pharmacist-in-charge, and compounding protocols.

Where to look: The pharmacy website and any intake documentation provided to the patient or prescriber.

Red flags: No physical address. Only a PO box or mail forwarder. Pharmacist-in-charge not named or not verifiable through the state board.

Years in operation and ownership clarity

What it measures: Tenure alone is not quality, but rapid ownership changes, name rebrands, or operations that appear and disappear inside a year are warning signs.

Where to look: State corporate records (Secretary of State business search), FDA facility registration history, and the pharmacy’s own disclosed history.

Red flags: Rebranded after a regulatory action. Ownership traced through multiple LLCs with no disclosed operator. Operating under a DBA that hides the entity of record.

Applying the framework

Open your target pharmacy’s website, then open the ten public databases listed in the framework in parallel tabs. Work top-to-bottom. If a criterion cannot be verified from public data, treat that as a signal in itself.

Starting in a later phase, we plan to publish a Compounding Pharmacy Safety Index using this exact rubric — with a public rating changelog, a published weighting for each criterion, and a due-process appeal channel for rated entities. Until that ships, this framework is the tool.

Why a data-first rubric, not a reputation list

Reputation-based recommendation lists for compounding pharmacies tend to drift into pay-for-placement, affiliate conflicts, or personal relationships that do not survive an adverse-event investigation. Public-record data does not drift in that way.

Every data point in this framework is retrievable by any patient, prescriber, or journalist. If a pharmacy disputes an evaluation, they can dispute the underlying public record, which either gets corrected by the source agency or stands.

The methodology is modeled on the facts-based consumer-rating model pioneered by Consumer Reports (90+ years), Charity Navigator, and Wirecutter: publish the rubric, publish the source, let the reader replicate.

Our relationship to rated entities

The Peptide Column accepts zero advertising, sponsorship, affiliate commission, or paid-audit revenue from any compounding pharmacy, past or present. This is a hard editorial rule that will not change. See our full methodology and affiliate disclosure.

Remember: a regulatory-clean pharmacy is still not a recommendation to use a compounded preparation. Any peptide decision belongs with a licensed healthcare provider who knows your medical history.